Brief: Arcutis Says New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement Of Atopic Dermatitis In Individuals With Diverse Skin Types
25/09/2024 06:02
Sept 25 (Reuters) - Arcutis Biotherapeutics Inc
ARQT.O :
* NEW DATA SHOWS ZORYVE® (ROFLUMILAST) CREAM 0.15% PROVIDED
CONSISTENT IMPROVEMENT OF ATOPIC DERMATITIS IN INDIVIDUALS WITH
DIVERSE SKIN TYPES
Source text for Eikon: ID:nGNX43G7dp
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf